FDA clears way for Phase 1/2a trial of stem cell therapy for Parkinson’s
The U.S. Food and Drug Administration (FDA) has given Aspen Neuroscience clearance to launch a clinical trial of ANPD001, an experimental stem cell therapy designed to replace the nerve cells that are lost in Parkinson’s disease. As planned, the open-label Phase 1/2a trial will test the safety,…